These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 29566831)

  • 1. The ICER Value Framework: Integrating Cost Effectiveness and Affordability in the Assessment of Health Care Value.
    Pearson SD
    Value Health; 2018 Mar; 21(3):258-265. PubMed ID: 29566831
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Health Economics Approach to US Value Assessment Frameworks-Summary and Recommendations of the ISPOR Special Task Force Report [7].
    Garrison LP; Neumann PJ; Willke RJ; Basu A; Danzon PM; Doshi JA; Drummond MF; Lakdawalla DN; Pauly MV; Phelps CE; Ramsey SD; Towse A; Weinstein MC
    Value Health; 2018 Feb; 21(2):161-165. PubMed ID: 29477394
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Review of Recent US Value Frameworks-A Health Economics Approach: An ISPOR Special Task Force Report [6].
    Willke RJ; Neumann PJ; Garrison LP; Ramsey SD
    Value Health; 2018 Feb; 21(2):155-160. PubMed ID: 29477393
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Objectives, Budgets, Thresholds, and Opportunity Costs-A Health Economics Approach: An ISPOR Special Task Force Report [4].
    Danzon PM; Drummond MF; Towse A; Pauly MV
    Value Health; 2018 Feb; 21(2):140-145. PubMed ID: 29477391
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incorporating Affordability Concerns Within Cost-Effectiveness Analysis for Health Technology Assessment.
    Lomas JRS
    Value Health; 2019 Aug; 22(8):898-905. PubMed ID: 31426931
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incorporating considerations of cost-effectiveness, affordability, and resource implications in guideline development: article 6 in Integrating and coordinating efforts in COPD guideline development. An official ATS/ERS workshop report.
    Hill SR; Olson LG; Falck-Ytter Y; Cruz AA; Atkins D; Baumann M; Jaeschke R; Woitalla T; Schünemann HJ;
    Proc Am Thorac Soc; 2012 Dec; 9(5):251-5. PubMed ID: 23256167
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Health Economics Approach to US Value Assessment Frameworks-Introduction: An ISPOR Special Task Force Report [1].
    Neumann PJ; Willke RJ; Garrison LP
    Value Health; 2018 Feb; 21(2):119-123. PubMed ID: 29477388
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Defining Elements of Value in Health Care-A Health Economics Approach: An ISPOR Special Task Force Report [3].
    Lakdawalla DN; Doshi JA; Garrison LP; Phelps CE; Basu A; Danzon PM
    Value Health; 2018 Feb; 21(2):131-139. PubMed ID: 29477390
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Budget impact analysis-principles of good practice: report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force.
    Sullivan SD; Mauskopf JA; Augustovski F; Jaime Caro J; Lee KM; Minchin M; Orlewska E; Penna P; Rodriguez Barrios JM; Shau WY
    Value Health; 2014; 17(1):5-14. PubMed ID: 24438712
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Defining and Measuring the Affordability of New Medicines: A Systematic Review.
    Antoñanzas F; Terkola R; Overton PM; Shalet N; Postma M
    Pharmacoeconomics; 2017 Aug; 35(8):777-791. PubMed ID: 28477220
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Affordability Challenges to Value-Based Pricing: Mass Diseases, Orphan Diseases, and Cures.
    Danzon PM
    Value Health; 2018 Mar; 21(3):252-257. PubMed ID: 29566830
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Principles of good practice for budget impact analysis: report of the ISPOR Task Force on good research practices--budget impact analysis.
    Mauskopf JA; Sullivan SD; Annemans L; Caro J; Mullins CD; Nuijten M; Orlewska E; Watkins J; Trueman P
    Value Health; 2007; 10(5):336-47. PubMed ID: 17888098
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Toward Relevant and Credible Cost-Effectiveness Analyses for Value Assessment in the Decentralized U.S. Health Care System.
    Jansen JP; Incerti D; Curtis JR
    J Manag Care Spec Pharm; 2019 May; 25(5):518-521. PubMed ID: 31039069
    [TBL] [Abstract][Full Text] [Related]  

  • 15. As Value Assessment Frameworks Evolve, Are They Finally Ready for Prime Time?
    Dubois RW; Westrich K
    Value Health; 2019 Sep; 22(9):977-980. PubMed ID: 31511186
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Economic evaluation of interventions in health care.
    McFarland A
    Nurs Stand; 2014 Nov; 29(10):49-58. PubMed ID: 25370268
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness thresholds in health care: a bookshelf guide to their meaning and use.
    Culyer AJ
    Health Econ Policy Law; 2016 Oct; 11(4):415-32. PubMed ID: 26906561
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Procedures and methods of benefit assessments for medicines in Germany].
    Bekkering GE; Kleijnen J
    Dtsch Med Wochenschr; 2008 Dec; 133 Suppl 7():S225-46. PubMed ID: 19034813
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Philosophical concerns regarding cost-effectiveness analyses.
    Weiner BK
    Med Hypotheses; 2010 Feb; 74(2):383-6. PubMed ID: 19651478
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.